Ignite Creation Date:
2024-05-05 @ 11:59 AM
Last Modification Date:
2024-10-26 @ 9:17 AM
Study NCT ID:
NCT00191997
Status:
COMPLETED
Last Update Posted:
2006-07-25
First Post:
2005-09-12
Brief Title:
Optimal Length of Treatment Continuation With Olanzapine After Remission of Manic or Mixed Episode
Sponsor:
Eli Lilly and Company
Organization:
Eli Lilly and Company
Study Overview
Official Title:
Optimal Treatment Duration With Olanzapine Following Remission of Manic or Mixed Episode An Open-Label Randomized Trial Comparing Two Treatment Strategies
Status:
COMPLETED
Status Verified Date:
2006-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a randomized parallel open-label study of patients who have responded to treatment in the acute phase of their manic or mixed episode with or without psychotic symptoms with olanzapine in mono or co-therapy and who are in syndromic and symptomatic remission at the time of enrollment into the study
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| F1D-XM-HGLW | None | None | None |